The role of FGF-23 in CKD-MBD and cardiovascular disease: Friend or foe?

Nephrology Dialysis Transplantation

Volumn 25, Issue 5, 2010, Pages 1376-1381

  Larsson, Tobias E ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Chronic kidney disease; FGF 23; Fibroblast growth factor 23; Klotho; Mortality; Phosphorous

Indexed keywords

BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR 23; PROTECTIVE AGENT; UREMIC TOXIN;

ATHEROSCLEROSIS; BONE DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DISEASE MARKER; GENE MUTATION; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERPHOSPHATEMIA; HYPOPARATHYROIDISM; IN VITRO STUDY; IN VIVO STUDY; MINERAL DEFICIENCY; MINERAL METABOLISM; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

BIOLOGICAL MARKERS; BONE DISEASES; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; FIBROBLAST GROWTH FACTORS; HUMANS; KIDNEY DISEASES; RISK FACTORS;

EID: 77951682465     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp784     Document Type: Review

References (64)

1. Consortium ADHR. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000; 26: 345-348
2. Jonsson KB, Zahradnik R, Larsson T, et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 2003; 348: 1656-1663 (Pubitemid 36459471)
3. Liu S, Guo R, Simpson LG, et al. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 2003; 278: 37419-37426 (Pubitemid 37175262)
4. Shimada T, Mizutani S, Muto T, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 2001; 98: 6500-6505 (Pubitemid 32488266)
5. Shimada T, Muto T, Urakawa I, et al. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteo-lytic cleavage and causes hypophosphatemia in vivo. Endocrinology 2002; 143: 3179-3182 (Pubitemid 34809892)
6. Saito H, Kusano K, Kinosaki M, et al. Human fibroblast growth fac-tor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha, 25-dihydroxyvitamin D3 production. J Biol Chem 2003; 278: 2206-2211 (Pubitemid 36801287)
7. Bai X, Miao D, Li J, et al. Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology 2004; 145: 5269-5279 (Pubitemid 39551149)
8. Larsson T, Marsell R, Schipani E, et al. Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 2004; 145: 3087-3094 (Pubitemid 38829975)
9. Shimada T, Kakitani M, Yamazaki Y, et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004; 113: 561-568 (Pubitemid 38542505)
10. Shimada T, Urakawa I, Yamazaki Y, et al. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun 2004; 314: 409-414 (Pubitemid 38084732)
11. Sitara D, Razzaque MS, Hesse M, et al. Homozygous ablation of fi-broblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol 2004; 23: 421-432 (Pubitemid 39576657)
12. Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004; 19: 429-435 (Pubitemid 38787398)
13. White KE, Carn G, Lorenz-Depiereux B, et al. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 2001; 60: 2079-2086 (Pubitemid 33070451)
14. Feng JQ, Ward LM, Liu S, et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 2006; 38: 1310-1315 (Pubitemid 44646294)
15. Lorenz-Depiereux B, Bastepe M, Benet-Pages A, et al. DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet 2006; 38: 1248-1250 (Pubitemid 44646286)
16. Topaz O, Shurman DL, Bergman R, et al. Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat Genet 2004; 36: 579-581 (Pubitemid 38715983)
17. Benet-Pages A, Orlik P, Strom TM, et al. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 2005; 14: 385-390 (Pubitemid 40220655)
18. Larsson T, Yu X, Davis SI, et al. A novel recessive mutation in fi-broblast growth factor-23 causes familial tumoral calcinosis. J Clin Endocrinol Metab 2005; 90: 2424-2427 (Pubitemid 40586293)
19. Krajisnik T, Bjorklund P, Marsell R, et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 2007; 195: 125-131 (Pubitemid 350056006)
20. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007; 117: 4003-4008 (Pubitemid 350224109)
21. Urakawa I, Yamazaki Y, Shimada T, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006; 444: 770-774 (Pubitemid 44949607)
22. Kuro-o M, Matsumura Y, Aizawa H, et al. Mutation of the mouse Klotho gene leads to a syndrome resembling ageing. Nature 1997; 390: 45-51 (Pubitemid 27494749)
23. Liu S, Vierthaler L, Tang W, et al. FGFR3 and FGFR4 do not mediate renal effects of FGF23. J Am Soc Nephrol 2008; 19: 2342-2350
24. Farrow EG, Davis SI, Summers LJ, et al. Initial FGF23-mediated signaling occurs in the distal convoluted tubule. J Am Soc Nephrol 2009; 20: 955-960
25. Riminucci M, Collins MT, Fedarko NS, et al. FGF-23 in fibrous dys-plasia of bone and its relationship to renal phosphate wasting. J Clin Invest 2003; 112: 683-692 (Pubitemid 38057709)
26. Liu S, Tang W, Zhou J, et al. Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice. Am J Physiol Endocrinol Metab 2007; 293: E1636-E1644 (Pubitemid 350255114)
27. Sitara D, Kim S, Razzaque MS, et al. Genetic evidence of serum phosphate-independent functions of FGF-23 on bone. PLoS Genet 2008; 4: e1000154
28. Wang H, Yoshiko Y, Yamamoto R, et al. Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro. J Bone Miner Res 2008; 23: 939-948 (Pubitemid 351768812)
29. Ito M, Sakai Y, Furumoto M, et al. Vitamin D and phosphate regulate fibroblast growth factor-23 in K-562 cells. Am J Physiol Endocrinol Metab 2005; 288: E1101-E1109 (Pubitemid 40726796)
30. Kolek OI, Hines ER, Jones MD, et al. 1alpha, 25-Dihydroxyvita-min D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skelet al axis that controls phosphate transport. Am J Physiol Gastrointest Liver Physiol 2005; 289: G1036-G1042
31. Antoniucci DM, Yamashita T, Portale AA. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab 2006; 91: 3144-3149 (Pubitemid 44271770)
32. Burnett SM, Gunawardene SC, Bringhurst FR, et al. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 2006; 21: 1187-1196
33. Ito N, Fukumoto S, Takeuchi Y, et al. Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humans. J Bone Miner Metab 2007; 25: 419-422 (Pubitemid 350043699)
34. Kawata T, Imanishi Y, Kobayashi K, et al. Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hy-perparathyroidism. J Am Soc Nephrol 2007; 18: 2683-2688 (Pubitemid 47531195)
35. Minamizaki T, Yoshiko Y, Yoshioka H, et al. A parathyroid hormone-1α, 25-dihydroxyvitamin D3-FGF23 loop regulating bone mineralization in cultured rat calvaria osteoblasts. ASBMR 31st Annual Meeting 2009
36. Wesseling-Perry K, Gales B, Wang H, et al. Skelet al responses to PTH: a comparison between low and high turnover renal osteodystro-phy. ASN Renal Week 2009
37. Yamashita H, Yamashita T, Miyamoto M, et al. Fibroblast growth factor (FGF)-23 in patients with primary hyperparathyroidism. Eur J Endocrinol 2004; 151: 55-60 (Pubitemid 39117364)
38. Gupta A, Winer K, Econs MJ, et al. FGF-23 is elevated by chronic hyperphosphatemia. J Clin Endocrinol Metab 2004; 89: 4489-4492 (Pubitemid 39244460)
39. Larsson T, Nisbeth U, Ljunggren O, et al. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003; 64: 2272-2279 (Pubitemid 37449564)
40. Weber TJ, Liu S, Indridason OS, et al. Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res 2003; 18: 1227-1234 (Pubitemid 37294915)
41. Shigematsu T, Kazama JJ, Yamashita T, et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 2004; 44: 250-256 (Pubitemid 38962552)
42. Gutierrez O, Isakova T, Rhee E, et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005; 16: 2205-2215 (Pubitemid 41716454)
43. Mirza MA, Larsson A, Lind L, et al. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis 2009; 205: 385-390
44. Nakanishi S, Kazama JJ, Nii-Kono T, et al. Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int 2005; 67: 1171-1178 (Pubitemid 41623344)
45. Bai X, Miao D, Goltzman D, et al. Early lethality in Hyp mice with targeted deletion of Pth gene. Endocrinology 2007; 148: 4974-4983 (Pubitemid 47481537)
46. Komaba H, Goto S, Fujii H, et al. Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int 2010; 77: 232-238
47. Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218
48. Wolf M, Shah A, Gutierrez O, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007; 72: 1004-1013 (Pubitemid 47530570)
49. Gutierrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-592
50. Jean G, Terrat JC, Vanel T, et al. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant 2009; 24: 2792-2796
51. Tonelli M, Sacks F, Pfeffer M, et al. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005; 112: 2627-2633 (Pubitemid 41532599)
52. Larsson TE, Olauson H, Hagstrom E, et al. Conjoint effects of serum calcium and phosphate on risk of total, cardiovascular, and noncar-diovascular mortality in the community. Arterioscler Thromb Vasc Biol 2009; November 30 Epub ahead of print
53. Dhingra R, Sullivan LM, Fox CS, et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 2007; 167: 879-885 (Pubitemid 46762749)
54. Mirza MA, Hansen T, Johansson L, et al. Relationship between circulating FGF23 and total body atherosclerosis in the community. Ne-phrol Dial Transplant 2009; 24: 3125-3131
55. Inaba M, Okuno S, Imanishi Y, et al. Role of fibroblast growth factor-23 in peripheral vascular calcification in non-diabetic and diabetic hemodialysis patients. Osteoporos Int 2006; 17: 1506-1513 (Pubitemid 44387485)
56. Roos M, Lutz J, Salmhofer H, et al. Relation between plasma fibro-blast growth factor-23, serum fetuin-A levels and coronary artery calcification evaluated by multislice computed tomography in patients with normal kidney function. Clin Endocrinol (Oxf) 2008; 68: 660-665 (Pubitemid 351388700)
57. Gutierrez OM, Januzzi JL, Isakova T, et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009; 119: 2545-2552
58. Jean G, Bresson E, Terrat JC, et al. Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences. Nephrol Dial Transplant 2009; 24: 948-955
59. Mirza MA, Larsson A, Melhus H, et al. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis 2009 Dec; 207: 546-551
60. Hsu HJ, Wu MS. Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients. Am J Med Sci 2009; 337: 116-122
61. Hughes SE. Differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal human adult tissues. J Histochem Cytochem 1997; 45: 1005-1019
62. Liu L, Pasumarthi KB, Padua RR, et al. Adult cardiomyocytes express functional high-affinity receptors for basic fibroblast growth factor. Am J Physiol 1995; 268: H1927-H1938
63. Pan QW, Ruan RX, Wheeler DA, et al. Fibroblast growth factor-23 inhibits inflammation-induced calcification in vitro in human vascular smooth muscle cells. ASN Renal Week 2009
64. Saji F, Shiizaki K, Shimada S, et al. Regulation of fibroblast growth factor 23 production in bone in uremic rats. Nephron Physiol 2009; 111: 59-66